Skip to main navigation Skip to search Skip to main content

Biochemical mechanism of HIV-1 resistance to rilpivirine

  • Kamalendra Singh
  • , Bruno Marchand
  • , Devendra K. Rai
  • , Bechan Sharma
  • , Eleftherios Michailidis
  • , Emily M. Ryan
  • , Kayla B. Matzek
  • , Maxwell D. Leslie
  • , Ariel N. Hagedorn
  • , Zhe Li
  • , Pieter R. Norden
  • , Atsuko Hachiya
  • , Michael A. Parniak
  • , Hong Tao Xu
  • , Mark A. Wainberg
  • , Stefan G. Sarafianos

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Reverse transcriptase mutations E138K and M184I emerged most frequently in HIV-1 patients who failed rilpivirine/emtricitabine/tenofovir combination therapy. Results: M184I reduces polymerase efficiency, and E138K restores it. E138K also reduces rilpivirine binding affinity mainly by increasing its dissociation rate. Conclusion: E138K abrogates the polymerase defect of M184I and increases rilpivirine dissociation. Significance: Our results provide a biochemical explanation for the selection of E138K/M184I in patients who failed combination therapy.

Original languageEnglish (US)
Pages (from-to)38110-38123
Number of pages14
JournalJournal of Biological Chemistry
Volume287
Issue number45
DOIs
StatePublished - Nov 2 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Biochemical mechanism of HIV-1 resistance to rilpivirine'. Together they form a unique fingerprint.

Cite this